STOCK TITAN
  1. Home
  2. News
  3. SIGA

Siga Technologie - SIGA STOCK NEWS

Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.

SIGA Technologies (SIGA) maintains this dedicated news hub for stakeholders tracking developments in biodefense therapeutics and public health preparedness. Access verified updates about the company's oral antiviral TPOXX, government contracts, and international health security initiatives.

This resource consolidates official announcements including regulatory milestones, strategic partnerships, and financial performance reports. Investors and public health professionals will find timely information on:

• TPOXX approvals and distribution updates
• Government procurement contracts
• Clinical research developments
• Financial disclosures and earnings
• Global health collaboration announcements

All content is sourced directly from company filings and press releases to ensure accuracy. Bookmark this page for efficient tracking of SIGA's progress in developing countermeasures against orthopoxviruses and other high-consequence pathogens.

News

SIGA Names Larry Miller General Counsel

Rhea-AI Summary
SIGA Technologies, Inc. appoints Larry Miller as general counsel, bringing over twenty years of biopharmaceutical industry experience to drive the company's success and growth strategies. Miller's expertise in commercial businesses, mergers and acquisitions, and corporate governance will aid in expanding SIGA's global reach and maximizing benefits for patients, customers, and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
none
-
News

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) reported strong financial results for 2023, with $131 million in product sales and $84 million in pre-tax operating income. The company declared a special cash dividend of $0.60 per share, showing a significant increase over the previous year. SIGA's revenue growth, international sales, and diversification efforts highlight its robust business model and sector leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.24%
Tags
earnings
-
News

SIGA Declares Special Cash Dividend of $0.60 Per Share

Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) declares a special cash dividend of $0.60 per share, a 33% increase over the previous year's dividend. The dividend will be paid on April 11, 2024, to shareholders of record as of March 26, 2024, showcasing the company's strong financial performance and commitment to generating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
dividends
News

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call on March 12th, 2024, to provide a business update. Dr. Diem Nguyen, CEO, and Daniel Luckshire, CFO, will participate. The call will be accessible via webcast and phone. Replay options will also be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
conferences earnings
-
News

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

Rhea-AI Summary
SIGA Technologies, Inc. announced the appointment of Diem Nguyen, Ph.D., as the new CEO, effective January 27, 2024. Dr. Nguyen will lead the company's efforts in developing antiviral therapies for infectious diseases, representing SIGA in engagements with government partners, and securing new contracts and partnerships. With a background in biotechnology and pharmaceuticals, Dr. Nguyen's appointment signals the company's commitment to advancing global health solutions and addressing unmet needs in healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
management
-
News

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

Rhea-AI Summary
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA) reported financial results for Q3 2023, including U.S. government orders for $113M of Oral TPOXX and $25M of IV TPOXX. European Commission signed a contract with anticipated initial orders of $18M for Oral TPOXX. Q3 2023 revenues were $9.2M, with a net loss of $0.4M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.59%
Tags
earnings
News

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

Rhea-AI Summary
SIGA Technologies, Inc. will host a webcast and conference call for a business update on November 7th, 2023. Participants can access the call via dial-in or live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

Rhea-AI Summary
SIGA Technologies announces the creation of a joint procurement mechanism for oral TPOXX by the European Commission's DG HERA, with an anticipated initial order value of $18 million. Total TPOXX orders in 2023 expected to reach approximately $164 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
News

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA

Rhea-AI Summary
Meridian Medical Technologies signs framework contract with the European Commission for the procurement of Tecovirimat SIGA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
News

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

Rhea-AI Summary
SIGA Technologies announces the appointment of Dr. Jay K. Varma as EVP and CMO, strengthening their medical affairs leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
Stock SIGA logo
Siga Technologie

Nasdaq:SIGA

SIGA Rankings

#2022 Ranked by Market Cap
#2208 Ranked by Dividends

SIGA Stock Data

427.91M
40.54M
43.2%
51.52%
5.74%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEW YORK